Chiesi Farmaceutici S.p.a.

This study tested whether adding a new inhaled drug called CHF6001 (Tanimilast) to standard asthma treatments could better control the disease in adults whose asthma was still poorly managed. Over 500 participants used the add-on inhaler or a placebo for a year to see if it reduc…

This study tested a new inhaled medication, CHF6001 (Tanimilast), as an add-on treatment for adults with severe COPD and chronic bronchitis. Over 3,900 participants, who were already on standard triple therapy, received the new drug or a placebo for one year. The main goal was to…

This large, year-long study tested whether adding a new inhaled drug called CHF6001 to standard triple therapy could better control COPD in people with chronic bronchitis. It aimed to see if the add-on treatment could reduce the number of serious breathing flare-ups and improve l…